Claims for Patent: 7,122,544

Summary for Patent: 7,122,544

Title:	Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
Abstract:	Compounds having activity as inhibitors of IKK are disclosed, particularly IKK-2. The compounds of this invention are anilinopyrimidine derivatives having the following structure: ##STR00001## wherein R.sub.1 and R.sub.6 are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.
Inventor(s):	Kois; Adam (San Diego, CA), MacFarlane; Karen J. (San Diego, CA), Satoh; Yoshitaka (San Diego, CA), Bhagwat; Shripad S. (San Diego, CA), Parnes; Jason S. (San Diego, CA), Palanki; Moorthy S. S. (Encinitas, CA), Erdman; Paul E. (San Diego, CA)
Assignee:	Signal Pharmaceuticals, LLC (San Diego, CA)
Application Number:	10/004,642
Patent Claims:	1. A compound having the structure: ##STR00545## or a pharmaceutically acceptable salt thereof, wherein: R.sub.1 is phenyl, naphthyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, or quinazolinyl, optionally substituted with one to four substituents independently selected from R.sub.7; R.sub.2 is hydrogen; R.sub.3 is hydrogen or lower alkyl; R.sub.4 represents one to four optional substituents, wherein each substituent is the same or different and independently selected from halogen, hydroxy, lower alkyl and lower alkoxy; R.sub.5 and R.sub.6 are the same or different and independently --R.sub.8, --(CH.sub.2).sub.aC(.dbd.O)R.sub.9, --CH.sub.2).sub.aC(.dbd.O)OR.sub.9, --(CH.sub.2).sub.aC(.dbd.O)NR.sub.9R.sub.10, --(CH.sub.2).sub.aC(.dbd.O)NR.sub.9(CH.sub.2).sub.bC(.dbd.O)R.sub.10, --(CH.sub.2).sub.aNR.sub.9C(.dbd.O)R.sub.10, --(CH.sub.2).sub.aNR.sub.11C(.dbd.O)NR.sub.9R.sub.10, --(CH.sub.2).sub.aOR.sub.9, --(CH.sub.2).sub.aSO.sub.cR.sub.9, or --(CH.sub.2).sub.aSO.sub.2NR.sub.9R.sub.10; or R.sub.5 and R.sub.6 taken together with the nitrogen atom to which they are attached to form a substituted or unsubstituted pyridyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, quinazolinyl, morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl, tetrahydrothiophenyl, tetrahydropyrimidinyl, or tetrahydrothiopyranyl; R.sub.7 is at each occurrence independently halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylakyl, sulfonylalkyl, hydroxyalkyl, phenyl or napbthyl, substituted phenyl or naphthyl, aralkyl, substituted aralkyl, substituted or unsubstituted pyridyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, quinazolinyl, morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl, tetrahydrothiophenyl, tetrahydropyrimidinyl, or tetrahydrothiopyranyl, heterocyclealkyl, substituted heterocyclealkyl, --C(.dbd.O)OR.sub.8, --OC(.dbd.O)R.sub.8, --C(.dbd.O)NR.sub.8R.sub.9, --C(.dbd.O)NR.sub.8OR.sub.9, --SO.sub.cR.sub.8, --SO.sub.cNR.sub.8R.sub.9, --NR.sub.8SO.sub.cR.sub.9, --NR.sub.8R.sub.9, --NR.sub.8C(.dbd.O)R.sub.9, --NR.sub.8C(.dbd.O)(CH.sub.2).sub.bOR.sub.9, --NR.sub.8C(.dbd.O)(CH.sub.2).sub.bR.sub.9, --O(CH.sub.2).sub.bNR.sub.8R.sub.9, or substituted or unsubstituted pyridyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, quinazolinyl, morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl, tetrahydrothiophenyl, tetrahydropyrimidinyl, or tetrahydrothiopyranyl fused to phenyl; R.sub.8, R.sub.9, R.sub.10, and R.sub.11 are the same or different and at each occurrence independently hydrogen, alkyl, substituted alkyl, phenyl or naphthyl, substituted phenyl or naphthyl, aralkyl, substituted arylalkyl, substituted or unsubstituted pyridyl, furyl, beazofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, beazothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, quinazolinyl, morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl, tetrahydrothiophenyl, tetrahydropyrimidinyl, or tetrahydrothiopyranyl, heterocyclealkyl or substituted heterocyclealkyl; or R.sub.8 and R.sub.9 taken together with the atom or atoms to which they are attached to form a substituted or unsubstituted pyridyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, beazimidazolyl, thiazolyl, beazothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, quinazolinyl, morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl, tetrahydrothiophenyl, tetrahydropyrimidinyl, or tetrahydrothiopyranyl; a and b are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4; and c is at each occurrence 0, 1 or 2. 2. The compound of claim 1 wherein R.sub.5 and R.sub.6, taken together with the nitrogen atom to which they are attached, form a substituted or unsubstituted morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl, tetrahydropirimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl or tetrahydrothiopyranyl. 3. The compound of claim 1 wherein R.sub.1 is phenyl or naphthyl. 4. The compound of claim 1 wherein R.sub.5 and R.sub.6, taken together with the nitrogen atom to which they are attached, form piperazinyl. 5. The compound of claim 1 wherein R.sub.5 and R.sub.6, taken together with the nitrogen atom to which they are attached, form piperidinyl. 6. The compound of claim 1 wherein R.sub.5 and R.sub.6, taken together with the nitrogen atom to which they are attached, form morpholinyl. 7. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier. 8. A method for treating a condition responsive to IKK-2 inhibition, comprising administering to a patient in need thereof and effective amount of a compound having the structure: ##STR00546## or a pharmaceutically acceptable salt thereof, wherein: R.sub.1 is phenyl, naphthyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, or quinazolinyl, optionally substituted with one to four substituents independently selected from R.sub.7; R.sub.2 and R.sub.3 are the same or different and are independently hydrogen or lower alkyl; R.sub.4 represents one to four optional substituents, wherein each substituent is the same or different and independently selected from halogen, hydroxy, lower alkyl or lower alkoxy; R.sub.5 and R.sub.6 are the same or different and independently --R.sub.8, --(CH.sub.2).sub.aC(.dbd.O)R.sub.9, --(CH.sub.2).sub.aC(.dbd.O)OR.sub.9, --(CH.sub.2).sub.aC(.dbd.O)NR.sub.9R.sub.10, --(CH.sub.2).sub.aC(.dbd.O)NR.sub.9(CH.sub.2).sub.bC(.dbd.O)R.sub.10, --(CH.sub.2).sub.aNR.sub.9C.dbd.(O)R.sub.10, --(CH.sub.2).sub.aNR.sub.11C(.dbd.O)NR.sub.9R.sub.10, --(CH.sub.2).sub.aOR.sub.9, --(CH.sub.2).sub.aSO.sub.cR.sub.9, or --(CH.sub.2).sub.aSO.sub.2NR.sub.9R.sub.10; or R.sub.5 and R.sub.6 taken together with the nitrogen atom to which they are attached to form a substituted or unsubstituted pyridyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, quinazolinyl, morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl, tetrahydrothiophenyl, tetrahydropyrimidinyl, or tetrahydrothiopyranyl; R.sub.7 is at each occurrence independently halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfmylakyl, sulfonylalkyl, hydroxyalkyl, phenyl or naphthyl, substituted phenyl or naphthyl, aralkyl, substituted aralkyl, substituted or unsubstituted pyridyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, quinazolinyl, morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl, tetrahydrothiophenyl, tetrahydropyrimidinyl, or tetrahydrothiopyranyl, heterocyclealkyl, substituted heterocyclealkyl, --C(.dbd.O)OR.sub.8, --OC(.dbd.O)R.sub.8, --C(.dbd.O)NR.sub.8R.sub.9, --C(.dbd.O)NR.sub.8OR.sub.9, --SO.sub.cR.sub.8, --SO.sub.cNR.sub.8R.sub.9, --NR.sub.8SO.sub.cR.sub.9, --NR.sub.8R.sub.9, --NR.sub.8C(.dbd.O)R.sub.9, --NR.sub.8C(.dbd.O)(CH.sub.2).sub.bOR.sub.9, --NR.sub.8C(.dbd.O)(CH.sub.2).sub.bR.sub.9, --O(CH.sub.2).sub.bNR.sub.8R.sub.9, or substituted or unsubstituted pyridyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, quinazolinyl, morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl, tetrahydrothiophenyl, tetrahydropyrirnidinyl, or tetrahydrothiopyranyl fused to phenyl; R.sub.8, R.sub.9, R.sub.10 and R.sub.11 are the same or different and at each occurrence independently hydrogen, alkyl, substituted alkyl, phenyl or naphthyl, substituted phenyl or naphthyl, aralkyl, substituted arylalkyl, substituted or unsubstituted pyridyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazuiyl, triazinyl, cinnolinyl, phthalazinyl, quinazolinyl, morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl, tetrahydrothiophenyl, tetrahydropyrimidinyl, or tetrahydrothiopyranyl, heterocyclealkyl or substituted heterocyclealkyl; or R.sub.8 and R.sub.9 taken together with the atom or atoms to which they are attached to form a substituted or unsubstituted pyridyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, plithalazinyl, quinazolinyl, morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazmyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl, tetrahydrothiophenyl, tetrahydropyrimidinyl, or tetrahydrothiopyranyl; a and b are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4; and c is at each occurrence 0, 1 or 2, wherein the condition is an inflammatory condition, an autoimmune condition, a cardiovascular condition, a metabolic condition, an ischemic condition, an infectious disease, stroke, epilepsy, Alzheimer's disease, Parkinson's disease or cancer. 9. A method for treating an inflammatory condition comprising administering to a patient in need thereof and effective amount of a compound having the structure: ##STR00547## or a pharmaceutically acceptable salt thereof, wherein: R.sub.1 is phenyl, nanhthyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, or quinazolinyl optionally substituted with one to four substituents independently selected from R.sub.7; R.sub.2 and R.sub.3 are the same or different and are independently hydrogen or lower alkyl; R.sub.4 represents one to four optional substituents, wherein each substituent is the same or different and independently selected from halogen, hydroxy, lower alkyl or lower alkoxy; R.sub.5 and R.sub.6 are the same or different and independently --R.sub.8, --(CH.sub.2).sub.aC(.dbd.O)R.sub.9, --(CH.sub.2).sub.aC(.dbd.O)OR.sub.9, --(CH.sub.2).sub.aC(.dbd.O)NR.sub.9R.sub.10, --(CH.sub.2).sub.aC(.dbd.O)NR.sub.9(CH.sub.2).sub.bC(.dbd.O)R.sub.10, --(CH.sub.2).sub.aNR.sub.9C(.dbd.O)R.sub.10, --(CH.sub.2).sub.aNR.sub.11C(.dbd.O)NR.sub.9R.sub.10, --(CH.sub.2).sub.aOR.sub.9, --(CH.sub.2).sub.aSO.sub.cR.sub.9, or --(CH.sub.2).sub.aSO.sub.2NR.sub.9R.sub.10; or R.sub.5 and R.sub.6 taken together with the nitrogen atom to which they are attached to form a substituted or unsubstituted pyridyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, quinazolinyl, morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl, tetrahydrothiophenyl, tetrahydropyrimidinyl, or tetrahydrothiopyranyl; R.sub.7 is at each occurrence independently halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylakyl, sulfonylalkyl, hydroxyalkyl, phenyl or naphthyl, substituted phenyl or naphthyl, aralkyl, substituted aralkyl, substituted or unsubstituted pyridyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, quinazolinyl, morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl, tetrahydrothiophenyl, tetrahydropyrimidinyl, or tetrahydrothiopyranyl, heterocyclealkyl, substituted heterocyclealkyl, --C(.dbd.O)OR.sub.8, --OC(.dbd.O)R.sub.8, --C(.dbd.O)NR.sub.8R.sub.9, --C(.dbd.O)NR.sub.8OR.sub.9, --SO.sub.cR.sub.8, --SO.sub.cNR.sub.8R.sub.9, --NR.sub.8SO.sub.cR.sub.9, --NR.sub.8R.sub.9, --NR.sub.8C(.dbd.O)R.sub.9, --NR.sub.8C(.dbd.O)(CH.sub.2).sub.bOR.sub.9, --NR.sub.8C(.dbd.O)(CH.sub.2).sub.bR.sub.9, --O(CH.sub.2).sub.bNR.sub.8R.sub.9, or substituted or unsubstituted pyridyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, quinazolinyl, morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, terrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl, tetrahydrothiophenyl, tetrahydropyrimidinyl, or tetrahydrothiopyranyl fused to phenyl; R.sub.8, R.sub.9, R.sub.10 and R.sub.11 are the same or different and at each occurrence independently hydrogen, alkyl, substituted alkyl, phenyl or naphthyl, substituted phenyl or naphthyl, aralkyl, substituted arylalkyl, substituted or unsubstituted pyridyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, quinazolinyl, morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl, tetrahydrothiophenyl, tetrahydropyrimidinyl, or tetrahydrothiopyranyl, heterocyclealkyl or substituted heterocyclealkyl; or R.sub.8 and R.sub.9 taken together with the atom or atoms to which they are attached to form a substituted or unsubstituted pyridyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, beazoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, quinazolinyl, morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl, tetrahydrothiophenyl, tetrahydropyrimidinyl, or tetrahydrothiopyranyl; a and b are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4; and c is at each occurrence 0, 1 or 2. 10. The method of claim 9 wherein the inflammatory condition is rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gout, asthma, bronchitis, allergic rhinitis, chronic obstructive pulmonary disease, cystic fibrosis, inflammatory bowel disease, irritable bowel syndrome, mucous colitis, ulcerative colitis, Crohn's disease, gastritis, esophagitis, hepatitis, pancreatitis, nephritis, psoriasis, eczema, dermatitis, multiple sclerosis, Lou Gehrig's disease, sepsis, conjunctivitis, acute respiratory distress syndrome, purpura, nasal polip or lupus erythematosus. 11. A method for treating an inflammatory condition comprising administering to a patient in need thereof an effective amount of a compound or pharmaceutically acceptable salt of the compound of claim 1. 12. The method of claim 11 further comprising administering an effective amount of an anti-inflammatory agent. 13. The method of claim 12, wherein the anti-inflammatory agent is salicylic acid, acetylsalicylic acid, methyl salicylate, diflunisal, salsalate, olsalazine, sulfasalazine, acetaminophen, indomethacin, sulindac, etodolac, mefenamic acid, meclofenamate sodium, tolmetin, ketorolac, dichiofenac, ibuprofen, naproxen, naproxen sodium, fenoprofen, ketoprofen, flurbinprofen, oxaprozin, piroxicam, meloxicam, ampiroxicam, droxicam, pivoxicam, tenoxicam, nabumetome, phenylbutazone, oxyphenbutazone, antipyrine, aminopyrine, apazone and nimesulide, zileuton, aurothioglucose, gold sodium thiomalate, auranofin, colchicine, allopurinol, probenecid, sulfinpyrazone, benzbromarone, enbrel, infliximab, anarkinra, celecoxib or rofecoxib. 14. The method of claim 11, wherein the inflammatory condition is rheumatoid arthritis, rheumatoid spondylitis, osteoarthm-itis, gout, asthma, bronchitis, allergic rhinitis, chronic obstructive pulmonary disease, cystic fibrosis, inflammatory bowel disease, irritable bowel syndrome, mucous colitis, ulcerative colitis, Crohn's disease, gastritis, esophagitis, hepatitis, pancreatitis, nephritis, psoriasis, eczema, dermatitis, multiple sclerosis, Lou Gehrig's disease, sepsis, conjunctivitis, acute respiratory distress syndrome, purpura, nasal polip or lupus erythematosus. 15. The method of claim 8 wherein the cardiovascular or metabolic condition is atherosclerosis, restenosis following angioplasty, left ventricular hypertrophy, Type II diabetes, osteoporosis, erectile dysfunction, cachexia, myocardial infraction, ischemic diseases of heart, kidney, liver, and brain, organ transplant rejection, graft versus host disease, endotoxin shock, or multiple organ failure. 16. The method of claim 8 wherein the infectious disease is a viral infection. 17. The method of claim 16 wherein the viral infection is caused by human immunodeficiency virus, hepatitis B virus, hepatitis C virus, human papilomavirus, human T-cell leukemia virus or Epstein-Barr virus. 18. The method of claim 8 wherein the cancer is of the colon, rectum, prostate, liver, lung, bronchus, pancreas, brain, head, neck, stomach, skin, kidney, cervix, blood, larynx, esophagus, mouth, pharynx, testes, urinary bladder, ovary or uterus. 19. The method of claim 18 further comprising administering an effective amount of an anti-cancer agent or radiation therapy. 20. The method of claim 19 wherein the anti-cancer agent is cyclophosphamide, Ifosfamide, trofosfamide, Chlorambucil, carmustine (BCNU), Lomustine (CCNU), busulfan, Treosulfan, Dacarbazine, Cisplatin, carboplatin, vincristine, Vinblastine, Vindesine, Vinorelbine, paclitaxel, Docetaxol, etoposide, Teniposide, Topotecan, 9-aminocamptothecin, camptoirinotecan, crisnatol, mytomycin C, methotrexate, Trimetrexate, mycophenolic acid, Tiazofurin, Ribavirin, EICAR, hydroxyurea, deferoxamine, 5-fluorouracil, Floxuridine, Doxifluridine, Ratitrexed, cytarabine (ara C), cytosine arabinoside, fludarabine, mercaptopurmne, thioguanine, Tamoxifen, Raloxifene, megestrol, goscrclin, Leuprolide acetate, flutamide, bicalutamide, B 1089, CB 1093, KH 1060, vertoporfin (BPD-MA), Phthalocyanine, photosensitizer Pc4, demethoxyhypocrellin A (2BA-2-DMHA), interferon-.alpha., interferon-.gamma., tumor-necrosis factor, Lovastatin, 1-methyl-4-phenylpyridinium ion, staurosporine, Actinomycin D, Dactinomycin, bleomycin A2, Bleomycin B2, Peplomycin, daunorubicin, Doxorubicin (adriamycin), Idarubicin, Epirubicin, Pirarubicin, Zorubicin, Mitoxantrone, verapamil or thapsigargin.

Details for Patent 7,122,544

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2020-12-06
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2020-12-06
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2020-12-06